Top Markets
Coin of the day
Lytix Biopharma AS Lytix Biopharma AS

Lytix Biopharma AS

LYTIX
Classement en actions #24450
Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology... Based in Oslo, Norway, Lytix Biopharma ASA is a clinical-stage biotechnology firm dedicated to advancing innovative immunotherapies for cancer treatment. Its primary drug candidate, LTX-315, is an oncolytic molecule currently undergoing Phase II clinical trials. This therapy is formulated for intratumoral injection, aiming to provide localized treatment for solid tumors. Additionally, Lytix Biopharma is developing LTX-401, another oncolytic molecule in its preclinical phase, specifically designed to target deep-seated cancerous lesions, including those found in liver cancer. The company was established in 2003.
Prix de l'action
$0.78611575
Capitalisation boursière
$60.45M
Changement (1 jour)
0.00%
Changement (1 an)
-12.06%
Pays
NO
Échange Lytix Biopharma AS (LYTIX)

Catégorie

Historique du rendement du dividende pour Lytix Biopharma AS (LYTIX)
Le rendement du dividende (TTM) de Lytix Biopharma AS (symbole boursier : LYTIX) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Lytix Biopharma AS (LYTIX) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH